var data={"title":"Treatment and prevention of bacterial sepsis in the preterm infant (<34 weeks gestation)","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Treatment and prevention of bacterial sepsis in the preterm infant (&lt;34 weeks gestation)</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/contributors\" class=\"contributor contributor_credentials\">Leonard E Weisman, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/contributors\" class=\"contributor contributor_credentials\">Mohan Pammi, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/contributors\" class=\"contributor contributor_credentials\">Joseph A Garcia-Prats, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/contributors\" class=\"contributor contributor_credentials\">Morven S Edwards, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/contributors\" class=\"contributor contributor_credentials\">Carrie Armsby, MD, MPH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jan 31, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H518453371\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Neonatal sepsis remains a major cause of neonatal mortality and morbidity in preterm and very low birth weight (VLBW) infants [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/1-5\" class=\"abstract_t\">1-5</a>]. Clinical care providers should have a high index of suspicion to diagnose infections in preterm and VLBW infants. Delay in initiation of appropriate antibiotic therapy can worsen clinical outcomes. (See <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of bacterial sepsis in the preterm infant (&lt;34 weeks gestation)&quot;</a>.)</p><p>The management of neonatal sepsis in preterm infants is reviewed here. The clinical features and diagnosis of sepsis in preterm infants, and the treatment of neonatal sepsis in term and late preterm infants are discussed separately. (See <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of bacterial sepsis in the preterm infant (&lt;34 weeks gestation)&quot;</a> and <a href=\"topic.htm?path=management-and-outcome-of-sepsis-in-term-and-late-preterm-infants\" class=\"medical medical_review\">&quot;Management and outcome of sepsis in term and late preterm infants&quot;</a>.)</p><p>In addition, there are separate topics on nosocomial viral infections and the management of candidal infections in the newborn. (See <a href=\"topic.htm?path=nosocomial-viral-infections-in-the-neonatal-intensive-care-unit\" class=\"medical medical_review\">&quot;Nosocomial viral infections in the neonatal intensive care unit&quot;</a> and <a href=\"topic.htm?path=treatment-of-candida-infection-in-neonates\" class=\"medical medical_review\">&quot;Treatment of Candida infection in neonates&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H518453378\"><span class=\"h1\">TERMINOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The following terms will be used throughout this topic:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Preterm infants are those born at less than 34 weeks gestation.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Late preterm infants (also called near-term infants) are those born between 34 and 36 completed weeks of gestation. Sepsis in late preterm infants is discussed in a separate topic review (see <a href=\"topic.htm?path=management-and-outcome-of-sepsis-in-term-and-late-preterm-infants\" class=\"medical medical_review\">&quot;Management and outcome of sepsis in term and late preterm infants&quot;</a>).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Very low birth weight (VLBW) infants: Infants with birth weights &lt;1500 g.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Sepsis: Defined as isolation of a pathogenic bacterium from a blood culture.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Early-onset sepsis (EOS) is defined as sepsis that occurs in the first 72 hours of life.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Late-onset sepsis (LOS) is defined as sepsis that occurs after the first 72 hours of life.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Healthcare-associated infections are defined as infections (eg, sepsis) acquired in the hospital while receiving treatment for other conditions [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/6\" class=\"abstract_t\">6</a>].</p><p/><p class=\"headingAnchor\" id=\"H176904710\"><span class=\"h1\">TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The management of sepsis in preterm infants consists of supportive care and antibiotic treatment, which includes initial empiric and organism-specific therapy. Although a variety of adjunctive interventions have been studied, <strong>none</strong> have been shown to improve the outcome of infants with sepsis.</p><p class=\"headingAnchor\" id=\"H176904823\"><span class=\"h2\">Supportive care</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Supportive care is initially focused on ensuring adequate systemic oxygenation and peripheral perfusion. In particular, aggressive resuscitative intervention is required in patients with fulminant sepsis, defined as severe sepsis or septic shock that is likely to result in death within 48 hours. (See <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation#H176899819\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of bacterial sepsis in the preterm infant (&lt;34 weeks gestation)&quot;, section on 'Severe sepsis and septic shock'</a> and <a href=\"topic.htm?path=etiology-clinical-manifestations-evaluation-and-management-of-neonatal-shock\" class=\"medical medical_review\">&quot;Etiology, clinical manifestations, evaluation, and management of neonatal shock&quot;</a>.)</p><p>General supportive care includes:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Optimal oxygenation &ndash; In some patients, supplemental oxygen or mechanical ventilatory support with endotracheal intubation may be required to ensure adequate oxygenation, especially in patients with initial inadequate perfusion. In patients who are already mechanically ventilated, ventilatory settings may need to be increased. In patients with concomitant neonatal pneumonia, surfactant therapy may be useful for improving respiratory function [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/7,8\" class=\"abstract_t\">7,8</a>]. (See <a href=\"topic.htm?path=noninvasive-oxygen-delivery-and-oxygen-monitoring-in-the-newborn\" class=\"medical medical_review\">&quot;Noninvasive oxygen delivery and oxygen monitoring in the newborn&quot;</a> and <a href=\"topic.htm?path=mechanical-ventilation-in-neonates\" class=\"medical medical_review\">&quot;Mechanical ventilation in neonates&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Maintenance of adequate perfusion:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In patients with inadequate perfusion, intravenous (IV) fluid resuscitation with the administration of isotonic saline may be necessary. Once adequate perfusion is obtained, ongoing management focuses on fluid and electrolyte balance. (See <a href=\"topic.htm?path=etiology-clinical-manifestations-evaluation-and-management-of-neonatal-shock#H2997754284\" class=\"medical medical_review\">&quot;Etiology, clinical manifestations, evaluation, and management of neonatal shock&quot;, section on 'Initial stabilization'</a> and <a href=\"topic.htm?path=fluid-and-electrolyte-therapy-in-newborns\" class=\"medical medical_review\">&quot;Fluid and electrolyte therapy in newborns&quot;</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Inotropic therapy may be required for patients with inadequate perfusion who fail to respond to aggressive fluid management. In these patients, <a href=\"topic.htm?path=dopamine-pediatric-drug-information\" class=\"drug drug_pediatric\">dopamine</a> infusion is generally used as the initial agent. (See <a href=\"topic.htm?path=etiology-clinical-manifestations-evaluation-and-management-of-neonatal-shock#H3483017469\" class=\"medical medical_review\">&quot;Etiology, clinical manifestations, evaluation, and management of neonatal shock&quot;, section on 'Vasoactive agents'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Maintenance of a thermoneutral environment.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Early removal of catheters that may be the foci of bacterial infection &ndash; Delayed removal (&gt;48 hours after diagnosis of sepsis) or failure to remove catheters are associated with an increased risk of complications (eg, end-organ damage and thrombocytopenia) and persistent bacteremia [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/9-11\" class=\"abstract_t\">9-11</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In some centers, including ours, extracorporeal membrane oxygenation (ECMO) may be offered to patients who have ongoing cardiorespiratory compromise (eg, hypoxic respiratory failure and shock) despite maximal medical management including aggressive fluid management and inotropic support. In our institution, ECMO for support of infants with severe refractory septic shock is limited to neonates who meet all of the following criteria:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Birth weight &gt;2 kg.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Gestational age &gt;34 weeks.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Duration of mechanical ventilation &lt;14 days with a diagnosis of reversible lung disease.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>No evidence of cyanotic heart disease.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>No other conditions that would be considered contraindications to ECMO, including multiple organ system failure; contraindications to full anticoagulation (eg, coagulopathy, grade 2 or greater intracranial hemorrhage); massive cerebral edema; irreversible pulmonary or cardiac disease; or multiple congenital anomalies.</p><p/><p class=\"headingAnchor\" id=\"H756107256\"><span class=\"h2\">Antibiotic therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Antibiotic therapy includes initial empiric and organism-specific therapy. However, because of increasing antibiotic resistance, the choice of antibiotic agents should be carefully selected to reduce the likelihood of antibiotic-resistant bacteria within each neonatal intensive care unit (NICU).</p><p class=\"headingAnchor\" id=\"H756105772\"><span class=\"h3\">Antibiotic resistance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There has been an increasing emergence of infections in preterm infants caused by antibiotic-resistant gram-negative bacteria [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/3,5,12\" class=\"abstract_t\">3,5,12</a>]. As an example, in one study from the National Institute of Child Health and Human Development (NICHD) Neonatal Research Network, 85 percent of early-onset <em>Escherichia coli</em> infections were resistant to <a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">ampicillin</a> [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/3,5\" class=\"abstract_t\">3,5</a>]. Risk factors associated with acquisition of antibiotic-resistant bacteria include very low birth weight (birth weight &lt;1500 g) and the exposure to third-generation cephalosporins.</p><p>Two mechanisms resulting in increased antibiotic resistance are production of the following (see <a href=\"topic.htm?path=extended-spectrum-beta-lactamases\" class=\"medical medical_review\">&quot;Extended-spectrum beta-lactamases&quot;</a>) [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/13-17\" class=\"abstract_t\">13-17</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Chromosomally-encoded or plasmid-derived AmpC beta-lactamases.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Plasmid-mediated extended-spectrum beta-lactamases (ESBLs) [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/13-17\" class=\"abstract_t\">13-17</a>]. Organisms that produce ESBLs, primarily <em>E. coli</em> and <em>Klebsiella</em> species, are resistant to penicillins, cephalosporins, and monobactams, and can be resistant to aminoglycosides.</p><p/><p>Currently, ESBL and AmpC beta-lactamase-producing organisms can be effectively treated using fourth-generation cephalosporins (eg, <a href=\"topic.htm?path=cefepime-pediatric-drug-information\" class=\"drug drug_pediatric\">cefepime</a>) [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/18,19\" class=\"abstract_t\">18,19</a>], and carbapenems (eg, <a href=\"topic.htm?path=meropenem-pediatric-drug-information\" class=\"drug drug_pediatric\">meropenem</a>) [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/20,21\" class=\"abstract_t\">20,21</a>]. Carbapenems (meropenem, <a href=\"topic.htm?path=imipenem-and-cilastatin-pediatric-drug-information\" class=\"drug drug_pediatric\">imipenem</a>) are a unique class of beta-lactam agents that are stable against most plasmid and chromosomal mediated beta-lactamases and are effective against more than 90 percent of ESBL-producing Enterobacteriaceae. Meropenem is the preferred carbapenem in newborn infants, as the safety profiles of other carbapenems have not been established in neonates [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/22\" class=\"abstract_t\">22</a>]. Although <a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">gentamicin</a> resistance is not common, the aminoglycosides <a href=\"topic.htm?path=amikacin-pediatric-drug-information\" class=\"drug drug_pediatric\">amikacin</a> or netilmicin, which are resistant to the aminoglycoside-modifying enzymes of the bacteria, can be used in patients who are infected with a gentamicin-resistant pathogen [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/23\" class=\"abstract_t\">23</a>].</p><p class=\"headingAnchor\" id=\"H756107268\"><span class=\"h3\">Empiric antibiotic therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Empiric antibiotic therapy should be initiated for infants with suspected sepsis once the evaluation has been completed because of the risk of death and severe morbidity (see <a href=\"#H518453481\" class=\"local\">'Outcomes'</a> below). The initial choice of parenteral antimicrobials for suspected sepsis in the preterm neonate is based on the likely pathogens, the susceptibility patterns of organisms in a particular nursery, and the presence of an apparent source of infection (eg, skin, joint, central line, or bone involvement).</p><p class=\"headingAnchor\" id=\"H176905105\"><span class=\"h4\">Early-onset sepsis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The combination of <a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">ampicillin</a> and <a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">gentamicin</a> is effective in treating most of the common pathogens that cause early-onset sepsis in preterm infants, such as group B <em>Streptococcus</em> (GBS) and <em>E. coli</em>. (See <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation#H176897141\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of bacterial sepsis in the preterm infant (&lt;34 weeks gestation)&quot;, section on 'Early-onset sepsis'</a> and <a href=\"topic.htm?path=management-and-outcome-of-sepsis-in-term-and-late-preterm-infants#H5\" class=\"medical medical_review\">&quot;Management and outcome of sepsis in term and late preterm infants&quot;, section on 'Early-onset sepsis'</a>.)</p><p>Because of the emergence of cephalosporin-resistant organisms, especially <em>Enterobacter</em>, <em>Klebsiella</em>, and <em>Serratia</em> species, the routine use of a third-generation cephalosporin to treat neonatal sepsis is not recommended, <strong>except</strong> for patients with suspected gram-negative bacterial meningitis because of its excellent penetration in the cerebrospinal fluid [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/17\" class=\"abstract_t\">17</a>]. (See <a href=\"topic.htm?path=bacterial-meningitis-in-the-neonate-treatment-and-outcome#H5\" class=\"medical medical_review\">&quot;Bacterial meningitis in the neonate: Treatment and outcome&quot;, section on 'Early-onset'</a>.)</p><p class=\"headingAnchor\" id=\"H176905161\"><span class=\"h4\">Late-onset sepsis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In preterm infants with late-onset sepsis (LOS) the choice of empiric antibiotic therapy should be based on the likely organism and its pattern of antibiotic susceptibility for a particular nursery, and the clinical setting.</p><p>In our center, the predominant causative organism for LOS in preterm infants is coagulase-negative staphylococci (CoNS), and both <em>Staphylococcus aureus</em> and gram-negative bacteria are common pathogens. As a result, we use a combination of <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> and <a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">gentamicin</a> as initial empiric antibiotic therapy for LOS while awaiting isolation of the causative organism from culture and its antibiotic susceptibility.</p><p>The IV dosing of <a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">ampicillin</a>, <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a>, and <a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">gentamicin</a> is dependent on age and renal function as follows [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/24\" class=\"abstract_t\">24</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">Ampicillin</a> &ndash; Ampicillin is based on chronologic age</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Infants &le;7 days of life &ndash; 150 <span class=\"nowrap\">mg/kg</span> per dose IV every 12 hours</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Infants &gt;7 days of life &ndash; 75 <span class=\"nowrap\">mg/kg</span> per dose IV every 6 hours</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">Vancomycin</a> &ndash; Vancomycin dosing is based on gestational age and serum creatinine (Scr; which will take approximately five days after birth to reflect neonatal renal function):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Gestational age &le;28 weeks [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/25\" class=\"abstract_t\">25</a>]:</p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Scr &lt;0.5 <span class=\"nowrap\">mg/dL:</span> 15 <span class=\"nowrap\">mg/kg/dose</span> IV every 12 hours</p><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Scr 0.5 to 0.7 <span class=\"nowrap\">mg/dL:</span> 20 <span class=\"nowrap\">mg/kg/dose</span> IV every 24 hours</p><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Scr 0.8 to 1 <span class=\"nowrap\">mg/dL:</span> 15 <span class=\"nowrap\">mg/kg/dose</span> IV every 24 hours</p><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Scr 1.1 to 1.4 <span class=\"nowrap\">mg/dL:</span> 10 <span class=\"nowrap\">mg/kg/dose</span> IV every 24 hours</p><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Scr &gt;1.4 <span class=\"nowrap\">mg/dL:</span> 15 <span class=\"nowrap\">mg/kg/dose</span> IV every 48 hours</p><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Scr &gt;1.6 <span class=\"nowrap\">mg/dL:</span> 15 <span class=\"nowrap\">mg/kg/dose</span> every 48 hours</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Gestational age &gt;28 weeks [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/22\" class=\"abstract_t\">22</a>]:</p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Scr &lt;0.7 <span class=\"nowrap\">mg/dL:</span> 15 <span class=\"nowrap\">mg/kg/dose</span> IV every 12 hours</p><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Scr 0.7 to 0.9 <span class=\"nowrap\">mg/dL:</span> 20 <span class=\"nowrap\">mg/kg/dose</span> IV every 24 hours</p><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Scr 1 to 1.2 <span class=\"nowrap\">mg/dL:</span> 15 <span class=\"nowrap\">mg/kg/dose</span> IV every 24 hours</p><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Scr 1.3 to 1.6 <span class=\"nowrap\">mg/dL:</span> 10 <span class=\"nowrap\">mg/kg/dose</span> IV every 24 hours</p><p/><p class=\"bulletIndent1\">Alternative weight-directed dosing recommendations are also available (refer to Lexicomp pediatric drug information).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">Gentamicin</a> &ndash; IV gentamicin dosing is based on both postmenstrual age (PMA) and chronologic age.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For infants &lt;29 weeks PMA:</p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Infants &le;7 days of life: 5 <span class=\"nowrap\">mg/kg</span> per dose IV every 48 hours</p><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Infants between 8 and 28 days of life: 4 <span class=\"nowrap\">mg/kg</span> per dose IV every 36 hours</p><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Infants &ge;29 days of life: 4 <span class=\"nowrap\">mg/kg</span> per dose IV every 24 hours</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For infants 30 to 34 weeks PMA:</p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Infants &le;7 days of life: 4.5 <span class=\"nowrap\">mg/kg</span> per dose IV every 36 hours</p><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Infants &gt;7 days of life: 4 <span class=\"nowrap\">mg/kg</span> per dose IV every 24 hours</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For infants &gt;34 weeks PMA: 4 <span class=\"nowrap\">mg/kg</span> per dose every 24 hours</p><p/><p>In addition, the following alternative regimens are used based on additional clinical factors:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>If meningitis is suspected, we add a broad-spectrum cephalosporin (eg, <a href=\"topic.htm?path=cefotaxime-pediatric-drug-information\" class=\"drug drug_pediatric\">cefotaxime</a>, if available).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>If an <em>S. aureus</em> infection is suspected, empiric therapy consists of <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a>, and <a href=\"topic.htm?path=nafcillin-pediatric-drug-information\" class=\"drug drug_pediatric\">nafcillin</a> or <a href=\"topic.htm?path=oxacillin-pediatric-drug-information\" class=\"drug drug_pediatric\">oxacillin</a>. <em>S. aureus</em> infection often presents as a focal site infection, such as soft tissue, skin, joint, or bone involvement.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>If gram-negative infection is suspected or the course is fulminant, we add <a href=\"topic.htm?path=ceftazidime-pediatric-drug-information\" class=\"drug drug_pediatric\">ceftazidime</a> for coverage of a potential <em>Pseudomonas</em> infection.</p><p/><p>In a retrospective study of 3339 neonates with <em>S. aureus</em> infection in 348 NICUs, inadequate empiric antibiotic therapy (defined as not including &ge;1 antibiotic with antistaphylococcal activity on day one of therapy) was associated with increased 30-day mortality (odds ratio [OR] 2.03 95% CI 1.08&ndash;3.82) among infants with infection due to methicillin-resistant <em>S. aureus</em> (MRSA), but not among those with methicillin-sensitive <em>S. aureus</em> (MSSA) infection [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/26\" class=\"abstract_t\">26</a>]. A similar study found that among neonates with LOS due to CoNS, <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> started on day one of therapy did not decrease 30-day mortality compared with delayed vancomycin therapy started after blood culture results, although it decreased the median duration of bacteremia by a day [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/27\" class=\"abstract_t\">27</a>].</p><p class=\"headingAnchor\" id=\"H518453457\"><span class=\"h3\">Organism-specific therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Empirical antimicrobial therapy is altered based upon the isolation of a pathogen and its pattern of antimicrobial susceptibility [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/16,28\" class=\"abstract_t\">16,28</a>]. In general, we use the following organism-specific parenteral antibiotic therapy:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>CoNS &ndash; <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">Vancomycin</a>.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>S. aureus</em> &ndash; Directed therapy is based on the sensitivity of the isolate to specific antibiotics. In cases caused by MSSA, therapy can be completed with a <a href=\"topic.htm?path=nafcillin-pediatric-drug-information\" class=\"drug drug_pediatric\">nafcillin</a> alone. In patients with MRSA, therapy can be completed with <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a>.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>E. coli</em> &ndash; Directed therapy is based on the sensitivity of the isolate to specific antibiotics. For infants with ampicillin-sensitive isolates, parenteral <a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">ampicillin</a> can be used alone. In those with ampicillin-resistant infection, either an appropriate aminoglycoside (<a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">gentamicin</a>), or an extended-spectrum cephalosporin (eg, <a href=\"topic.htm?path=cefotaxime-pediatric-drug-information\" class=\"drug drug_pediatric\">cefotaxime</a>, if available) can be used.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>Klebsiella</em> and <em>Serratia</em> &ndash; These species are often ESBL-producing organisms. The drug of choice for ESBL-producing organisms is <a href=\"topic.htm?path=meropenem-pediatric-drug-information\" class=\"drug drug_pediatric\">meropenem</a> [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/17\" class=\"abstract_t\">17</a>]. If the organism is susceptible, an aminoglycoside (particularly <a href=\"topic.htm?path=amikacin-pediatric-drug-information\" class=\"drug drug_pediatric\">amikacin</a>, which is the most active against ESBL-producing organisms) or <a href=\"topic.htm?path=cefepime-pediatric-drug-information\" class=\"drug drug_pediatric\">cefepime</a> can be used.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>Enterobacter</em> or <em>Citrobacter</em> &ndash; These species are also likely to be ESBL-producing organisms. The drug of choice for ESBL-producing organisms is <a href=\"topic.htm?path=meropenem-pediatric-drug-information\" class=\"drug drug_pediatric\">meropenem</a>. If the organism is susceptible, an aminoglycoside (particularly <a href=\"topic.htm?path=amikacin-pediatric-drug-information\" class=\"drug drug_pediatric\">amikacin</a>, which is the most active against ESBL-producing organism) or <a href=\"topic.htm?path=cefepime-pediatric-drug-information\" class=\"drug drug_pediatric\">cefepime</a> can be used.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>Pseudomonas</em> &ndash; Combination therapy of <a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">gentamicin</a>, and <a href=\"topic.htm?path=ceftazidime-pediatric-drug-information\" class=\"drug drug_pediatric\">ceftazidime</a> or <a href=\"topic.htm?path=piperacillin-united-states-not-available-drug-information\" class=\"drug drug_general\">piperacillin</a><span class=\"nowrap\">/tazobactam</span>.</p><p/><p>Of note, neonates should not receive <a href=\"topic.htm?path=ceftriaxone-pediatric-drug-information\" class=\"drug drug_pediatric\">ceftriaxone</a> intravenously if they also are receiving, or are expected to receive, IV calcium in any form, including parenteral nutrition. The combination of this therapy is associated with adverse cardiopulmonary events [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/29\" class=\"abstract_t\">29</a>].</p><p class=\"headingAnchor\" id=\"H756105056\"><span class=\"h3\">Duration and response to therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Duration of antibiotic therapy is usually 10 to 14 days for uncomplicated blood stream infections [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/17,30\" class=\"abstract_t\">17,30</a>]. However, length of therapy is longer in patients with meningitis; two to three weeks of antibiotic therapy for gram-positive meningitis, and a minimum of three weeks for gram-negative meningitis.</p><p>The decision to continue antibiotic therapy in an infant with negative cultures is based on the clinical judgment of the attending neonatologists. However, as noted below, the judicious use of antibiotics is strongly encouraged to reduce the prevalence of antibiotic-resistant bacteria and fungal infections. (See <a href=\"#H756107397\" class=\"local\">'Infection control measures'</a> below.)</p><p class=\"headingAnchor\" id=\"H518453399\"><span class=\"h2\">Adjunct therapy to antibiotics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A variety of adjunctive immunotherapeutic interventions has been evaluated, but none have been shown to conclusively improve the outcome of infants with sepsis [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/31,32\" class=\"abstract_t\">31,32</a>]. These therapies include intravenous <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information\" class=\"drug drug_pediatric\">immune globulin</a> (IVIG) infusions [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/33,34\" class=\"abstract_t\">33,34</a>], granulocyte (white blood cells) transfusions [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/35\" class=\"abstract_t\">35</a>], granulocyte and granulocyte-macrophage colony-stimulating factor administration [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/36\" class=\"abstract_t\">36</a>], and <a href=\"topic.htm?path=pentoxifylline-pediatric-drug-information\" class=\"drug drug_pediatric\">pentoxifylline</a> [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/37\" class=\"abstract_t\">37</a>]. Based on available data, these interventions should <strong>not</strong> be routinely administered.</p><p class=\"headingAnchor\" id=\"H756106808\"><span class=\"h3\">Intravenous immune globulin (IVIG)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Immunoglobulin binds to cell surface receptors, provides opsonic activity, activates complement, and improves antibody-dependent cytotoxicity and neutrophil function. It has been proposed that administration of polyclonal IVIG can benefit preterm infants with serious bacterial infection who are less than 32 weeks gestation, as most of the fetal transfer of maternal immunoglobulin occurs after 32 weeks gestation. However, several trials have failed to demonstrate that IVIG administration has significant clinical benefit for neonates with suspected <span class=\"nowrap\">and/or</span> confirmed sepsis [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/33,34\" class=\"abstract_t\">33,34</a>]. Based on the available evidence, we do <strong>not</strong> recommend the routine administration of IVIG for neonatal sepsis.</p><p>Research efforts are also ongoing to determine whether monoclonal antibodies targeted for specific organisms might be effective in treating neonatal sepsis [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/38\" class=\"abstract_t\">38</a>].</p><p class=\"headingAnchor\" id=\"H756106971\"><span class=\"h3\">Granulocyte transfusion or growth factors</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Granulocyte transfusions</strong> &ndash; In a systematic review, the routine use of granulocyte transfusions did not reduce mortality or morbidity in neonates with neonatal sepsis [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/35\" class=\"abstract_t\">35</a>]. Pulmonary complication was the only adverse effect that was reported in 4 of 44 infants who were included in the review. As a result, we do <strong>not</strong> recommend the routine administration of granulocyte transfusion for neonatal sepsis.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF</strong>) &ndash; In a systematic review, the routine use of G-CSF and GM-CSF did not reduce mortality of neonatal sepsis [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/39\" class=\"abstract_t\">39</a>]. In addition, the prophylactic use of growth factors did not reduce the risk of systemic infection in high-risk patients. In a subgroup analysis of 97 patients with neutropenia defined as a white cell count &lt;1.7 x 10<sup>9</sup><span class=\"nowrap\">/L,</span> there was a reduction in morality by day 14 of life, however, the authors of the review suggest that further investigation is needed as the sample size was too small to determine whether growth factors are beneficial. In a follow-up study of one of the trials in the systematic review, the administration of GM-CSF had no effect on neurodevelopmental, general health, or educational outcomes at five years of age [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/40\" class=\"abstract_t\">40</a>]. Based on the available evidence, we do <strong>no</strong>t recommend the routine administration of G-CSF and GM-CSF for neonatal sepsis.</p><p/><p class=\"headingAnchor\" id=\"H518453406\"><span class=\"h3\">Pentoxifylline</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=pentoxifylline-pediatric-drug-information\" class=\"drug drug_pediatric\">Pentoxifylline</a>, a xanthine derivative, inhibits the release of tumor necrosis factor (TNF)-alpha, which is generally associated w<sup>i</sup>th systemic gram-negative infection. Limited data suggest that the addition of pentoxifylline to antibiotic therapy reduces mortality in neonates with sepsis. In a meta-analysis of six trials that included 416 neonates, pentoxifylline therapy was associated with a decrease in all-cause mortality during hospital stay (relative risk [RR] 0.57, 95% CI 0.35-0.93; low quality evidence) [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/41\" class=\"abstract_t\">41</a>]. However, large multicenter trials are needed to confirm the effectiveness of pentoxifylline before it can be recommended routinely in the treatment of neonatal sepsis.</p><p class=\"headingAnchor\" id=\"H518453427\"><span class=\"h1\">PREVENTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Prevention of neonatal sepsis due to healthcare-associated infections focuses primarily on infection control measures.</p><p class=\"headingAnchor\" id=\"H756107397\"><span class=\"h2\">Infection control measures</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The following infection control measures that reduce the incidence of late-onset sepsis (LOS) were recommended in a report from the American Academy of Pediatrics (AAP) Committees on Fetus and Newborn and Infectious Diseases [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/42\" class=\"abstract_t\">42</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hand hygiene remains one of the most effective methods for reducing healthcare-associated infections [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/43\" class=\"abstract_t\">43</a>]. The following recommendations for hand hygiene were developed by the World Health Organization [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/44\" class=\"abstract_t\">44</a>]:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Wash visibly soiled hands (dirt, blood, or other body fluids) with soap and water.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For all clinical settings in which the hands are not visibly soiled, use an alcohol-based hand rub. Products should have a low irritant potential and be in accessible dispensers at the point of care. Alternative hand hygiene products should be provided to staff with a confirmed allergy or adverse reaction to standard products.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In our institution, jewelry and watches are removed before hand washing and remain off until after contact with the newborn. Sleeves of clothing should remain above the elbows during hand hygiene and while caring for patients. Each patient has a dedicated stethoscope that is cleaned with alcohol before and after each use.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Adherence to hand hygiene before and after direct patient contact, including: handling an invasive device (regardless of whether gloves are worn); contact with body fluids, nonintact skin, mucous membranes, or wound dressing; moving from one contaminated site to another during care of the same patient (eg, moving from dressing a surgical wound to caring for an intravenous vascular site); after contact with inanimate surfaces and objects; and after glove removal.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Use of gloves does not replace the need for hand hygiene. Gloves are worn when there is reasonably anticipated contact with blood or other potentially infectious materials or body sites. Gloves should be replaced after each patient contact or when moving from one contaminated site to another during care of the same patient. One study from a tertiary neonatal intensive care unit (NICU) reported that nonsterile gloves used in addition to hand hygiene for patient and line contact reduced gram-positive bloodstream infections, and may have reduced central line-associated blood stream infections [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/45\" class=\"abstract_t\">45</a>]. Further investigation is needed to see if glove use should be initiated for all patient and line contact.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Do not wear artificial nails, and natural nails should be kept short. In our center, nails cannot extend past the tip of the finger to prevent tearing of gloves, and must be kept clean to decrease the potential spread of pathogens to patients [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/46-49\" class=\"abstract_t\">46-49</a>]. Nail polish may be worn if well-manicured, but chipped nail polish must be removed. Artificial nails or artificial nail products (eg, tips, jewelry, overlays, wraps) may not be worn.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Promote education and feedback from the staff regarding hand hygiene programs.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Monitor healthcare workers' hand hygiene adherence and provide feedback on their performance.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In neonates with central lines, strategies to prevent catheter-related blood stream infections (CRBSIs) include:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Setting and adhering to institutional guidelines for the insertion and care of indwelling lines [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/50,51\" class=\"abstract_t\">50,51</a>]. Guidelines should include the use of sterile technique and antiseptic agents at the site during line placement, daily monitoring of catheter sites, and redressing and cleaning the site on a weekly basis. Tubing used to infuse dextrose and amino acids should be replaced every four to seven days. Catheters should be removed promptly when they are no longer essential because the risk of infection generally increases with time; however, studies investigating the effect of dwell time on risk of infection with peripherally inserted central catheters (PICCs) have been contradictory [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/52,53\" class=\"abstract_t\">52,53</a>]. We do not recommend routine use of antibiotic lock therapy for prevention of CRBSI in neonates. In a meta-analysis of three studies (271 infants), antibiotic lock therapy appeared to be effective in preventing CRBSI in neonates [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/54\" class=\"abstract_t\">54</a>]. However, studies have not comprehensively assessed the effect of this intervention on development of resistant organisms. (See <a href=\"topic.htm?path=prevention-of-intravascular-catheter-related-infections#H17\" class=\"medical medical_review\">&quot;Prevention of intravascular catheter-related infections&quot;, section on 'Site care'</a> and <a href=\"topic.htm?path=prevention-of-intravascular-catheter-related-infections#H25\" class=\"medical medical_review\">&quot;Prevention of intravascular catheter-related infections&quot;, section on 'Catheter care'</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Use of closed system of drug delivery [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/55\" class=\"abstract_t\">55</a>].</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Promotion of early enteral feeding with breast milk, thereby reducing the need for or length of use of central venous lines and <a href=\"topic.htm?path=total-parenteral-nutrition-drug-information\" class=\"drug drug_general\">total parenteral nutrition</a>.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Judicious use of antibiotic therapy to reduce the risk of antibiotic resistance and fungal infection [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/12,56\" class=\"abstract_t\">12,56</a>]. This includes limiting antibiotic therapy to clinical situations in which bacterial infection is likely, discontinuing empirical therapy when a bacterial infection is not identified, and changing therapy to the narrowest spectrum based on susceptibility testing. In particular, restricting the use of <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> may reduce the prevalence of vancomycin-resistant enterococci, and restricting third-generation broad spectrum cephalosporins may decrease the induction of extended-spectrum beta-lactamases. (See <a href=\"#H756105772\" class=\"local\">'Antibiotic resistance'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Other measures of infection control include avoidance of overcrowding, and monitoring and surveillance of nosocomial infection including bacterial agents and their antibiotic susceptibility [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/57\" class=\"abstract_t\">57</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Continued quality improvement focused on increasing healthcare staff awareness and education, establishing common improvement goals, training, environmental care, and setting guidelines for patient care [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/58\" class=\"abstract_t\">58</a>].</p><p/><p class=\"headingAnchor\" id=\"H756107404\"><span class=\"h2\">Potential prophylactic therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Potential prophylactic interventions include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Lactoferrin</strong> &ndash; Lactoferrin, an iron-binding glycoprotein and a component of the mammalian innate response to infection, has been used prophylactically to prevent neonatal sepsis. It is the major whey protein in colostrum, breast milk, tears, and saliva. The available evidence suggests that lactoferrin has some efficacy in reducing risk of LOS [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/59\" class=\"abstract_t\">59</a>]; however, in light of the preliminary nature of these studies, we suggest not routinely using lactoferrin for the prevention of LOS pending further larger, multicenter studies.</p><p/><p class=\"bulletIndent1\">A 2017 meta-analysis of six randomized controlled trials reported that oral lactoferrin supplementation decreased the risk of LOS (relative risk [RR] 0.59, 95% CI 0.40-0.87; low quality evidence), but did not have a significant effect on all-cause mortality (RR 0.65, 95% CI 0.37-1.11). [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/59\" class=\"abstract_t\">59</a>]. Oral lactoferrin supplementation in combination with a probiotic also decreased LOS (RR 0.27, 95% CI 0.12-0.60; one study, low quality evidence). There were no reported adverse effects. Several large clinical trials are being undertaken to determine whether prophylactic lactoferrin is a cost-effective and safe preventive measure to reduce LOS in preterm infants [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/60\" class=\"abstract_t\">60</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Probiotics</strong> &ndash; We suggest not routinely using probiotics (defined as live nonpathogenic microbial preparations that colonize the intestine) for the prevention of LOS in preterm infants since their efficacy in preventing LOS is unproven. The combinations of organisms and dosing of these agents that are safe and efficacious have not been established.</p><p/><p class=\"bulletIndent1\">In two meta-analyses published in 2014, probiotics were not associated with decreased rate of LOS although they were associated with lower rates of necrotizing enterocolitis (NEC) and lower mortality in preterm infants [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/61,62\" class=\"abstract_t\">61,62</a>]. None of the preterm infants suffered sepsis due to probiotic organisms. In a 2016 meta-analysis of 37 trials, probiotics were associated with a small, but statistically significant, reduction in the risk of LOS compared with placebo or no treatment (13.9 versus 16.3 percent; relative risk 0.86, 95% CI 0.78&ndash;0.94) [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/63\" class=\"abstract_t\">63</a>].</p><p/><p class=\"bulletIndent1\">In a subsequently published trial, representing the largest trial to date, probiotics did not reduce the incidence of LOS [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/64\" class=\"abstract_t\">64</a>]. In this multicenter double-blinded randomized placebo-controlled trial involving &gt;1300 preterm neonates (gestational age 23 to 30 weeks), treatment with the probiotic <em>Bifidobacterium breve</em> BBG-001 was not associated with reduction in sepsis (RR 0.97, 95% CI 0.73-1.29), NEC (RR 0.93, 95% CI 0.68-1.27), or mortality (RR 0.93, 95% CI 0&middot;67-1.30) compared with placebo [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/64\" class=\"abstract_t\">64</a>].</p><p/><p class=\"bulletIndent1\">In another large randomized controlled trial of 1099 very preterm infants (gestational age &lt;32 weeks and birth weight &lt;1500 g), rates of culture-proven LOS were similar in infants who received a probiotic combination of <em>Bifidobacterium infantis, Streptococcus thermophilus, and Bifidobacterium lactis</em> and those who received placebo (13 and 16 percent, respectively) [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/65\" class=\"abstract_t\">65</a>].</p><p/><p class=\"bulletIndent1\">The use of probiotics for prevention of NEC is discussed in detail separately. (See <a href=\"topic.htm?path=prevention-of-necrotizing-enterocolitis-in-newborns\" class=\"medical medical_review\">&quot;Prevention of necrotizing enterocolitis in newborns&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H518453481\"><span class=\"h1\">OUTCOMES</span></p><p class=\"headingAnchor\" id=\"H518453435\"><span class=\"h2\">Mortality</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Neonatal sepsis remains a major cause of death in very low birth weight infants with reported incidences of 25 percent in early-onset sepsis and 18 percent in late-onset sepsis (LOS) [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/4,5,66\" class=\"abstract_t\">4,5,66</a>]. Mortality due to gram-negative infections is higher than that due to gram-positive infections at all ages of onset of sepsis [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/5,67-72\" class=\"abstract_t\">5,67-72</a>]. LOS that is fulminant (lethal within 48 hours) is more likely to be caused by gram-negative organisms [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/68\" class=\"abstract_t\">68</a>]. </p><p>In a single-center study of 424 very low birth weight infants with LOS, factors that were independently associated with increased risk of mortality included [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/71\" class=\"abstract_t\">71</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Gram-negative or fungal pathogen</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Need for intubation</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Need for vasopressor therapy</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hypoglycemia</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Thrombocytopenia</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Necrotizing enterocolitis (NEC)</p><p/><p class=\"headingAnchor\" id=\"H176903023\"><span class=\"h2\">Morbidity</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Preterm infants with sepsis are at risk for both short-term and long-term complications [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/66\" class=\"abstract_t\">66</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Short-term complications &ndash; Sepsis increases the risk of patent ductus arteriosus, prolonged ventilation, prolonged need for intravascular access, bronchopulmonary dysplasia, NEC, and duration of hospital stay [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/4\" class=\"abstract_t\">4</a>]. Neonatal gram-negative infections compared with gram-positive infections are associated with a longer length of hospital stay and higher healthcare costs [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/73\" class=\"abstract_t\">73</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Long-term complications &ndash; Sepsis is a risk factor for long-term neurodevelopmental impairment either by direct infection of the central nervous system or indirectly due to inflammation [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/74-78\" class=\"abstract_t\">74-78</a>]. In a prospective study from the National Institute of Child Health and Human Development (NICHD) Neonatal Research Network of 6093 extremely low birth weight infants (birth weight &lt;1000 g), survivors who had sepsis as a neonate (n = 1922) were more likely than those without an episode of neonatal sepsis to have an adverse neurodevelopmental outcome at 18 to 22 months of corrected gestational age [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/75\" class=\"abstract_t\">75</a>]. This included higher rates of cerebral palsy, lower Bayley Scales of Infant Development II scores, and increased vision impairment compared with uninfected infants.</p><p/><p class=\"headingAnchor\" id=\"H1490290933\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-sepsis-in-neonates\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Sepsis in neonates&quot;</a> and <a href=\"topic.htm?path=society-guideline-links-group-b-streptococcal-infection-in-pregnant-women-and-neonates\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Group B streptococcal infection in pregnant women and neonates&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H518453489\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>General supportive care for preterm infants with bacterial sepsis includes maintaining optimal oxygenation, adequate perfusion, and a thermoneutral environment. Catheters that may be foci of bacterial infection should be removed promptly once the diagnosis of sepsis is made (ideally within 48 hours). (See <a href=\"#H176904823\" class=\"local\">'Supportive care'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We recommend preterm infants with suspected sepsis be treated initially with empiric antibiotic therapy that provides broad coverage for the most likely pathogens (ie, for early-onset sepsis, group B <em>Streptococcus</em> and <em>Escherichia coli; </em>for late-onset sepsis, coagulase-negative staphylococci, <em>Staphylococcus aureus,</em> and gram-negative bacteria) (<a href=\"grade.htm?i=2\" class=\"grade\">Grade 1B</a>). (See <a href=\"#H756107268\" class=\"local\">'Empiric antibiotic therapy'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The empiric regimen for early-onset sepsis consists of a beta-lactam antibiotic (eg, <a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">ampicillin</a>) plus an aminoglycoside (eg, <a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">gentamicin</a>). (See <a href=\"#H176905105\" class=\"local\">'Early-onset sepsis'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The empiric regimen for late-onset sepsis in preterm infants during the birth hospitalization consists of <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> plus an aminoglycoside (most commonly <a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">gentamicin</a>). Alternate regimens may substitute <a href=\"topic.htm?path=nafcillin-pediatric-drug-information\" class=\"drug drug_pediatric\">nafcillin</a> or <a href=\"topic.htm?path=oxacillin-pediatric-drug-information\" class=\"drug drug_pediatric\">oxacillin</a> for vancomycin to decrease vancomycin exposure. (See <a href=\"#H176905161\" class=\"local\">'Late-onset sepsis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antibiotic therapy is altered based upon isolation of the causative agent and its antimicrobial susceptibility pattern. (See <a href=\"#H518453457\" class=\"local\">'Organism-specific therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Duration of therapy depends on the results of blood culture and clinical course. For uncomplicated bloodstream infections, antibiotic therapy is continued for 10 to 14 days. For infants with negative cultures, the decision to continue or stop antibiotic therapy is individualized based on the clinical status of the neonate and the judgment of the attending neonatologist. In general, antibiotic therapy should be discontinued if the infant is well-appearing and culture is negative after 48 hours, since sepsis is unlikely in this setting. (See <a href=\"#H756105056\" class=\"local\">'Duration and response to therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We suggest <strong>not</strong> routinely using of adjunctive immunotherapy (eg, intravenous <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information\" class=\"drug drug_pediatric\">immune globulin</a>, granulocyte transfusion, granulocyte and granulocyte-macrophage colony-stimulating factor, or <a href=\"topic.htm?path=pentoxifylline-pediatric-drug-information\" class=\"drug drug_pediatric\">pentoxifylline</a>) (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). (See <a href=\"#H518453399\" class=\"local\">'Adjunct therapy to antibiotics'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Prevention of neonatal sepsis due to healthcare-associated infections focuses primarily on infection control measures including hand hygiene, adherence to guidelines for the insertion and maintenance of indwelling lines to prevent central-line infections to reduce the incidence of sepsis, and judicious use of antibiotic therapy. (See <a href=\"#H756107397\" class=\"local\">'Infection control measures'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Neonatal sepsis remains a major cause for neonatal mortality and morbidity in preterm and very low birth weight infants. (See <a href=\"#H518453481\" class=\"local\">'Outcomes'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/1\" class=\"nounderline abstract_t\">Lawn JE, Wilczynska-Ketende K, Cousens SN. Estimating the causes of 4 million neonatal deaths in the year 2000. Int J Epidemiol 2006; 35:706.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/2\" class=\"nounderline abstract_t\">Stoll BJ, Hansen N. Infections in VLBW infants: studies from the NICHD Neonatal Research Network. Semin Perinatol 2003; 27:293.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/3\" class=\"nounderline abstract_t\">Stoll BJ, Hansen N, Fanaroff AA, et al. Changes in pathogens causing early-onset sepsis in very-low-birth-weight infants. N Engl J Med 2002; 347:240.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/4\" class=\"nounderline abstract_t\">Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002; 110:285.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/5\" class=\"nounderline abstract_t\">Stoll BJ, Hansen NI, Higgins RD, et al. Very low birth weight preterm infants with early onset neonatal sepsis: the predominance of gram-negative infections continues in the National Institute of Child Health and Human Development Neonatal Research Network, 2002-2003. Pediatr Infect Dis J 2005; 24:635.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/6\" class=\"nounderline abstract_t\">Polin RA, Denson S, Brady MT, et al. Epidemiology and diagnosis of health care-associated infections in the NICU. Pediatrics 2012; 129:e1104.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/7\" class=\"nounderline abstract_t\">Finer NN. Surfactant use for neonatal lung injury: beyond respiratory distress syndrome. Paediatr Respir Rev 2004; 5 Suppl A:S289.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/8\" class=\"nounderline abstract_t\">Recommendations for neonatal surfactant therapy. Paediatr Child Health 2005; 10:109.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/9\" class=\"nounderline abstract_t\">Benjamin DK Jr, Miller W, Garges H, et al. Bacteremia, central catheters, and neonates: when to pull the line. Pediatrics 2001; 107:1272.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/10\" class=\"nounderline abstract_t\">Nazemi KJ, Buescher ES, Kelly RE Jr, Karlowicz MG. Central venous catheter removal versus in situ treatment in neonates with enterobacteriaceae bacteremia. Pediatrics 2003; 111:e269.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/11\" class=\"nounderline abstract_t\">Karlowicz MG, Furigay PJ, Croitoru DP, Buescher ES. Central venous catheter removal versus in situ treatment in neonates with coagulase-negative staphylococcal bacteremia. Pediatr Infect Dis J 2002; 21:22.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/12\" class=\"nounderline abstract_t\">Tsai MH, Chu SM, Hsu JF, et al. Risk factors and outcomes for multidrug-resistant Gram-negative bacteremia in the NICU. Pediatrics 2014; 133:e322.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/13\" class=\"nounderline abstract_t\">Gupta A. Hospital-acquired infections in the neonatal intensive care unit--Klebsiella pneumoniae. Semin Perinatol 2002; 26:340.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/14\" class=\"nounderline abstract_t\">Gupta A, Ampofo K, Rubenstein D, Saiman L. Extended spectrum beta lactamase-producing Klebsiella pneumoniae infections: a review of the literature. J Perinatol 2003; 23:439.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/15\" class=\"nounderline abstract_t\">Pessoa-Silva CL, Meurer Moreira B, C&acirc;mara Almeida V, et al. Extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a neonatal intensive care unit: risk factors for infection and colonization. J Hosp Infect 2003; 53:198.</a></li><li class=\"breakAll\">American Academy of Pediatrics. Antimicrobial resistance and antimicrobial stewardship: Appropriate and judicious use of antimicrobial agents. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed, Kimberlin DW (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.874.</li><li class=\"breakAll\">American Academy of Pediatrics. Escherichia coli and other Gram-negative bacilli (septicemia and meningitis in neonates). In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed, Kimberlin DW (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.340.</li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/18\" class=\"nounderline abstract_t\">Capparelli E, Hochwald C, Rasmussen M, et al. Population pharmacokinetics of cefepime in the neonate. Antimicrob Agents Chemother 2005; 49:2760.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/19\" class=\"nounderline abstract_t\">Jones RN, Sader HS, Fritsche TR, Pottumarthy S. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagn Microbiol Infect Dis 2007; 57:109.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/20\" class=\"nounderline abstract_t\">Edwards JR. Meropenem: a microbiological overview. J Antimicrob Chemother 1995; 36 Suppl A:1.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/21\" class=\"nounderline abstract_t\">Hoban DJ, Jones RN, Yamane N, et al. In vitro activity of three carbapenem antibiotics. Comparative studies with biapenem (L-627), imipenem, and meropenem against aerobic pathogens isolated worldwide. Diagn Microbiol Infect Dis 1993; 17:299.</a></li><li class=\"breakAll\">American Academy of Pediatrics. Tables of antibacterial drug dosages, Table 4.2. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed, Kimberlin DW (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.882.</li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/23\" class=\"nounderline abstract_t\">Muscato JJ, Wilbur DW, Stout JJ, Fahrlender RA. An evaluation of the susceptibility patterns of gram-negative organisms isolated in cancer centres with aminoglycoside usage. J Antimicrob Chemother 1991; 27 Suppl C:1.</a></li><li class=\"breakAll\">Medications. In: Guidelines for Acute Care of the Neonate, 22nd ed, Adams JM, Fernandes CJ (Eds), Baylor College of Medicine, Houston, TX 2014. p.89.</li><li class=\"breakAll\">Nelson's Pocket Book of Pediatric Antimicrobial Therapy, 21st ed, Bradley JS, Nelson JD, Kimberlin DK (Eds), American Academy of Pediatrics, 2015.</li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/26\" class=\"nounderline abstract_t\">Thaden JT, Ericson JE, Cross H, et al. Survival Benefit of Empirical Therapy for Staphylococcus aureus Bloodstream Infections in Infants. Pediatr Infect Dis J 2015; 34:1175.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/27\" class=\"nounderline abstract_t\">Ericson JE, Thaden J, Cross HR, et al. No survival benefit with empirical vancomycin therapy for coagulase-negative staphylococcal bloodstream infections in infants. Pediatr Infect Dis J 2015; 34:371.</a></li><li class=\"breakAll\">Puopolo KM. Bacterial and fungal infections. In: Manual of Neonatal Care, Cloherty JP, Eichenwald EC, Stark AR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia, PA 2008. p.274.</li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/29\" class=\"nounderline abstract_t\">Bradley JS, Wassel RT, Lee L, Nambiar S. Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events. Pediatrics 2009; 123:e609.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/30\" class=\"nounderline abstract_t\">Pourcyrous M, Bada HS, Korones SB, et al. Significance of serial C-reactive protein responses in neonatal infection and other disorders. Pediatrics 1993; 92:431.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/31\" class=\"nounderline abstract_t\">Gerdes JS. Diagnosis and management of bacterial infections in the neonate. Pediatr Clin North Am 2004; 51:939.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/32\" class=\"nounderline abstract_t\">Cohen-Wolkowiez M, Benjamin DK Jr, Capparelli E. Immunotherapy in neonatal sepsis: advances in treatment and prophylaxis. Curr Opin Pediatr 2009; 21:177.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/33\" class=\"nounderline abstract_t\">INIS Collaborative Group, Brocklehurst P, Farrell B, et al. Treatment of neonatal sepsis with intravenous immune globulin. N Engl J Med 2011; 365:1201.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/34\" class=\"nounderline abstract_t\">Ohlsson A, Lacy JB. Intravenous immunoglobulin for suspected or proven infection in neonates. Cochrane Database Syst Rev 2015; :CD001239.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/35\" class=\"nounderline abstract_t\">Mohan P, Brocklehurst P. Granulocyte transfusions for neonates with confirmed or suspected sepsis and neutropaenia. Cochrane Database Syst Rev 2003; :CD003956.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/36\" class=\"nounderline abstract_t\">Schibler KR, Osborne KA, Leung LY, et al. A randomized, placebo-controlled trial of granulocyte colony-stimulating factor administration to newborn infants with neutropenia and clinical signs of early-onset sepsis. Pediatrics 1998; 102:6.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/37\" class=\"nounderline abstract_t\">Lauterbach R, Pawlik D, Kowalczyk D, et al. Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: a placebo-controlled, double-blind trial. Crit Care Med 1999; 27:807.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/38\" class=\"nounderline abstract_t\">Weisman LE, Thackray HM, Steinhorn RH, et al. A randomized study of a monoclonal antibody (pagibaximab) to prevent staphylococcal sepsis. Pediatrics 2011; 128:271.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/39\" class=\"nounderline abstract_t\">Carr R, Modi N, Dor&eacute; C. G-CSF and GM-CSF for treating or preventing neonatal infections. Cochrane Database Syst Rev 2003; :CD003066.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/40\" class=\"nounderline abstract_t\">Marlow N, Morris T, Brocklehurst P, et al. A randomised trial of granulocyte-macrophage colony-stimulating factor for neonatal sepsis: childhood outcomes at 5&#8197;years. Arch Dis Child Fetal Neonatal Ed 2015; 100:F320.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/41\" class=\"nounderline abstract_t\">Pammi M, Haque KN. Pentoxifylline for treatment of sepsis and necrotizing enterocolitis in neonates. Cochrane Database Syst Rev 2015; :CD004205.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/42\" class=\"nounderline abstract_t\">Polin RA, Denson S, Brady MT, et al. Strategies for prevention of health care-associated infections in the NICU. Pediatrics 2012; 129:e1085.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/43\" class=\"nounderline abstract_t\">Pessoa-Silva CL, Hugonnet S, Pfister R, et al. Reduction of health care associated infection risk in neonates by successful hand hygiene promotion. Pediatrics 2007; 120:e382.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/44\" class=\"nounderline abstract_t\">Pittet D, Allegranzi B, Boyce J, World Health Organization World Alliance for Patient Safety First Global Patient Safety Challenge Core Group of Experts. The World Health Organization Guidelines on Hand Hygiene in Health Care and their consensus recommendations. Infect Control Hosp Epidemiol 2009; 30:611.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/45\" class=\"nounderline abstract_t\">Kaufman DA, Blackman A, Conaway MR, Sinkin RA. Nonsterile glove use in addition to hand hygiene to prevent late-onset infection in preterm infants: randomized clinical trial. JAMA Pediatr 2014; 168:909.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/46\" class=\"nounderline abstract_t\">Larson EL. APIC guideline for handwashing and hand antisepsis in health care settings. Am J Infect Control 1995; 23:251.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/47\" class=\"nounderline abstract_t\">Edel E, Houston S, Kennedy V, LaRocco M. Impact of a 5-minute scrub on the microbial flora found on artificial, polished, or natural fingernails of operating room personnel. Nurs Res 1998; 47:54.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/48\" class=\"nounderline abstract_t\">McNeil SA, Foster CL, Hedderwick SA, Kauffman CA. Effect of hand cleansing with antimicrobial soap or alcohol-based gel on microbial colonization of artificial fingernails worn by health care workers. Clin Infect Dis 2001; 32:367.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/49\" class=\"nounderline abstract_t\">Moolenaar RL, Crutcher JM, San Joaquin VH, et al. A prolonged outbreak of Pseudomonas aeruginosa in a neonatal intensive care unit: did staff fingernails play a role in disease transmission? Infect Control Hosp Epidemiol 2000; 21:80.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/50\" class=\"nounderline abstract_t\">O'grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. Am J Infect Control 2002; 30:476.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/51\" class=\"nounderline abstract_t\">Fisher D, Cochran KM, Provost LP, et al. Reducing central line-associated bloodstream infections in North Carolina NICUs. Pediatrics 2013; 132:e1664.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/52\" class=\"nounderline abstract_t\">Milstone AM, Reich NG, Advani S, et al. Catheter dwell time and CLABSIs in neonates with PICCs: a multicenter cohort study. Pediatrics 2013; 132:e1609.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/53\" class=\"nounderline abstract_t\">Greenberg RG, Cochran KM, Smith PB, et al. Effect of Catheter Dwell Time on Risk of Central Line-Associated Bloodstream Infection in Infants. Pediatrics 2015; 136:1080.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/54\" class=\"nounderline abstract_t\">Taylor JE, Tan K, Lai NM, McDonald SJ. Antibiotic lock for the prevention of catheter-related infection in neonates. Cochrane Database Syst Rev 2015; :CD010336.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/55\" class=\"nounderline abstract_t\">Aly H, Herson V, Duncan A, et al. Is bloodstream infection preventable among premature infants? A tale of two cities. Pediatrics 2005; 115:1513.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/56\" class=\"nounderline abstract_t\">Kuppala VS, Meinzen-Derr J, Morrow AL, Schibler KR. Prolonged initial empirical antibiotic treatment is associated with adverse outcomes in premature infants. J Pediatr 2011; 159:720.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/57\" class=\"nounderline abstract_t\">Adams-Chapman I, Stoll BJ. Prevention of nosocomial infections in the neonatal intensive care unit. Curr Opin Pediatr 2002; 14:157.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/58\" class=\"nounderline abstract_t\">Schelonka RL, Scruggs S, Nichols K, et al. Sustained reductions in neonatal nosocomial infection rates following a comprehensive infection control intervention. J Perinatol 2006; 26:176.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/59\" class=\"nounderline abstract_t\">Pammi M, Suresh G. Enteral lactoferrin supplementation for prevention of sepsis and necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev 2017; 6:CD007137.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/60\" class=\"nounderline abstract_t\">ELFIN Trial Investigators Group. Lactoferrin immunoprophylaxis for very preterm infants. Arch Dis Child Fetal Neonatal Ed 2013; 98:F2.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/61\" class=\"nounderline abstract_t\">AlFaleh K, Anabrees J. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev 2014; :CD005496.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/62\" class=\"nounderline abstract_t\">Yang Y, Guo Y, Kan Q, et al. A meta-analysis of probiotics for preventing necrotizing enterocolitis in preterm neonates. Braz J Med Biol Res 2014; 47:804.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/63\" class=\"nounderline abstract_t\">Rao SC, Athalye-Jape GK, Deshpande GC, et al. Probiotic Supplementation and Late-Onset Sepsis in Preterm Infants: A Meta-analysis. Pediatrics 2016; 137:e20153684.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/64\" class=\"nounderline abstract_t\">Costeloe K, Hardy P, Juszczak E, et al. Bifidobacterium breve BBG-001 in very preterm infants: a randomised controlled phase 3 trial. Lancet 2016; 387:649.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/65\" class=\"nounderline abstract_t\">Jacobs SE, Tobin JM, Opie GF, et al. Probiotic effects on late-onset sepsis in very preterm infants: a randomized controlled trial. Pediatrics 2013; 132:1055.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/66\" class=\"nounderline abstract_t\">Bakhuizen SE, de Haan TR, Teune MJ, et al. Meta-analysis shows that infants who have suffered neonatal sepsis face an increased risk of mortality and severe complications. Acta Paediatr 2014; 103:1211.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/67\" class=\"nounderline abstract_t\">Gordon A, Isaacs D. Late onset neonatal Gram-negative bacillary infection in Australia and New Zealand: 1992-2002. Pediatr Infect Dis J 2006; 25:25.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/68\" class=\"nounderline abstract_t\">Karlowicz MG, Buescher ES, Surka AE. Fulminant late-onset sepsis in a neonatal intensive care unit, 1988-1997, and the impact of avoiding empiric vancomycin therapy. Pediatrics 2000; 106:1387.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/69\" class=\"nounderline abstract_t\">Makhoul IR, Sujov P, Smolkin T, et al. Pathogen-specific early mortality in very low birth weight infants with late-onset sepsis: a national survey. Clin Infect Dis 2005; 40:218.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/70\" class=\"nounderline abstract_t\">Benjamin DK, DeLong E, Cotten CM, et al. Mortality following blood culture in premature infants: increased with Gram-negative bacteremia and candidemia, but not Gram-positive bacteremia. J Perinatol 2004; 24:175.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/71\" class=\"nounderline abstract_t\">Levit O, Bhandari V, Li FY, et al. Clinical and laboratory factors that predict death in very low birth weight infants presenting with late-onset sepsis. Pediatr Infect Dis J 2014; 33:143.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/72\" class=\"nounderline abstract_t\">Piening BC, Geffers C, Gastmeier P, Schwab F. Pathogen-specific mortality in very low birth weight infants with primary bloodstream infection. PLoS One 2017; 12:e0180134.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/73\" class=\"nounderline abstract_t\">Stone PW, Gupta A, Loughrey M, et al. Attributable costs and length of stay of an extended-spectrum beta-lactamase-producing Klebsiella pneumoniae outbreak in a neonatal intensive care unit. Infect Control Hosp Epidemiol 2003; 24:601.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/74\" class=\"nounderline abstract_t\">Adams-Chapman I, Stoll BJ. Neonatal infection and long-term neurodevelopmental outcome in the preterm infant. Curr Opin Infect Dis 2006; 19:290.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/75\" class=\"nounderline abstract_t\">Stoll BJ, Hansen NI, Adams-Chapman I, et al. Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection. JAMA 2004; 292:2357.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/76\" class=\"nounderline abstract_t\">van Vliet EO, de Kieviet JF, Oosterlaan J, van Elburg RM. Perinatal infections and neurodevelopmental outcome in very preterm and very low-birth-weight infants: a meta-analysis. JAMA Pediatr 2013; 167:662.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/77\" class=\"nounderline abstract_t\">Alshaikh B, Yusuf K, Sauve R. Neurodevelopmental outcomes of very low birth weight infants with neonatal sepsis: systematic review and meta-analysis. J Perinatol 2013; 33:558.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation/abstract/78\" class=\"nounderline abstract_t\">Mitha A, Foix-L'H&eacute;lias L, Arnaud C, et al. Neonatal infection and 5-year neurodevelopmental outcome of very preterm infants. Pediatrics 2013; 132:e372.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 89456 Version 28.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H518453489\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H518453371\" id=\"outline-link-H518453371\">INTRODUCTION</a></li><li><a href=\"#H518453378\" id=\"outline-link-H518453378\">TERMINOLOGY</a></li><li><a href=\"#H176904710\" id=\"outline-link-H176904710\">TREATMENT</a><ul><li><a href=\"#H176904823\" id=\"outline-link-H176904823\">Supportive care</a></li><li><a href=\"#H756107256\" id=\"outline-link-H756107256\">Antibiotic therapy</a><ul><li><a href=\"#H756105772\" id=\"outline-link-H756105772\">- Antibiotic resistance</a></li><li><a href=\"#H756107268\" id=\"outline-link-H756107268\">- Empiric antibiotic therapy</a><ul><li><a href=\"#H176905105\" id=\"outline-link-H176905105\">Early-onset sepsis</a></li><li><a href=\"#H176905161\" id=\"outline-link-H176905161\">Late-onset sepsis</a></li></ul></li><li><a href=\"#H518453457\" id=\"outline-link-H518453457\">- Organism-specific therapy</a></li><li><a href=\"#H756105056\" id=\"outline-link-H756105056\">- Duration and response to therapy</a></li></ul></li><li><a href=\"#H518453399\" id=\"outline-link-H518453399\">Adjunct therapy to antibiotics</a><ul><li><a href=\"#H756106808\" id=\"outline-link-H756106808\">- Intravenous immune globulin (IVIG)</a></li><li><a href=\"#H756106971\" id=\"outline-link-H756106971\">- Granulocyte transfusion or growth factors</a></li><li><a href=\"#H518453406\" id=\"outline-link-H518453406\">- Pentoxifylline</a></li></ul></li></ul></li><li><a href=\"#H518453427\" id=\"outline-link-H518453427\">PREVENTION</a><ul><li><a href=\"#H756107397\" id=\"outline-link-H756107397\">Infection control measures</a></li><li><a href=\"#H756107404\" id=\"outline-link-H756107404\">Potential prophylactic therapy</a></li></ul></li><li><a href=\"#H518453481\" id=\"outline-link-H518453481\">OUTCOMES</a><ul><li><a href=\"#H518453435\" id=\"outline-link-H518453435\">Mortality</a></li><li><a href=\"#H176903023\" id=\"outline-link-H176903023\">Morbidity</a></li></ul></li><li><a href=\"#H1490290933\" id=\"outline-link-H1490290933\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H518453489\" id=\"outline-link-H518453489\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=bacterial-meningitis-in-the-neonate-treatment-and-outcome\" class=\"medical medical_review\">Bacterial meningitis in the neonate: Treatment and outcome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-and-diagnosis-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation\" class=\"medical medical_review\">Clinical features and diagnosis of bacterial sepsis in the preterm infant (&lt;34 weeks gestation)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=etiology-clinical-manifestations-evaluation-and-management-of-neonatal-shock\" class=\"medical medical_review\">Etiology, clinical manifestations, evaluation, and management of neonatal shock</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=extended-spectrum-beta-lactamases\" class=\"medical medical_review\">Extended-spectrum beta-lactamases</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=fluid-and-electrolyte-therapy-in-newborns\" class=\"medical medical_review\">Fluid and electrolyte therapy in newborns</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-and-outcome-of-sepsis-in-term-and-late-preterm-infants\" class=\"medical medical_review\">Management and outcome of sepsis in term and late preterm infants</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=mechanical-ventilation-in-neonates\" class=\"medical medical_review\">Mechanical ventilation in neonates</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=noninvasive-oxygen-delivery-and-oxygen-monitoring-in-the-newborn\" class=\"medical medical_review\">Noninvasive oxygen delivery and oxygen monitoring in the newborn</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=nosocomial-viral-infections-in-the-neonatal-intensive-care-unit\" class=\"medical medical_review\">Nosocomial viral infections in the neonatal intensive care unit</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prevention-of-intravascular-catheter-related-infections\" class=\"medical medical_review\">Prevention of intravascular catheter-related infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prevention-of-necrotizing-enterocolitis-in-newborns\" class=\"medical medical_review\">Prevention of necrotizing enterocolitis in newborns</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-group-b-streptococcal-infection-in-pregnant-women-and-neonates\" class=\"medical medical_society_guidelines\">Society guideline links: Group B streptococcal infection in pregnant women and neonates</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-sepsis-in-neonates\" class=\"medical medical_society_guidelines\">Society guideline links: Sepsis in neonates</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-candida-infection-in-neonates\" class=\"medical medical_review\">Treatment of Candida infection in neonates</a></li></ul></div></div>","javascript":null}